{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Perez DR"],"funding":["NCATS NIH HHS","NHLBI NIH HHS","National Institutes of Health (USA)","NCI NIH HHS","NIH Minority Institutional Research Training Program","UNM Autophagy Inflammation and Metabolism CoBRE","UNM Clinical and Translational Science Center","UNM Comprehensive Cancer Center","NIGMS NIH HHS"],"pagination":["155-163"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6571072"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["199"],"pubmed_abstract":["Clioquinol, one of the first mass-produced drugs, was considered safe and efficacious for many years. It was used as an antifungal and an antiprotozoal drug until it was linked to an outbreak of subacute myelo-optic neuropathy (SMON), a debilitating disease almost exclusively confined to Japan. Today, new information regarding clioquinol targets and its mechanism of action, as well as genetic variation (SNPs) in efflux transporters in the Japanese population, provide a unique interpretation of the existing phenomena. Further understanding of clioquinol's role in the inhibition of cAMP efflux and promoting apoptosis might offer promise for the treatment of cancer and/or neurodegenerative diseases. Here, we highlight recent developments in the field and discuss possible connections, hypotheses and perspectives in clioquinol-related research."],"journal":["Pharmacology & therapeutics"],"pubmed_title":["Clioquinol: To harm or heal."],"pmcid":["PMC6571072"],"funding_grant_id":["T32 HL007736","P20 GM121176","UL1TR001449","P30 CA118100","UL1 TR001449"],"pubmed_authors":["Sklar LA","Chigaev A","Perez DR"],"additional_accession":[]},"is_claimable":false,"name":"Clioquinol: To harm or heal.","description":"Clioquinol, one of the first mass-produced drugs, was considered safe and efficacious for many years. It was used as an antifungal and an antiprotozoal drug until it was linked to an outbreak of subacute myelo-optic neuropathy (SMON), a debilitating disease almost exclusively confined to Japan. Today, new information regarding clioquinol targets and its mechanism of action, as well as genetic variation (SNPs) in efflux transporters in the Japanese population, provide a unique interpretation of the existing phenomena. Further understanding of clioquinol's role in the inhibition of cAMP efflux and promoting apoptosis might offer promise for the treatment of cancer and/or neurodegenerative diseases. Here, we highlight recent developments in the field and discuss possible connections, hypotheses and perspectives in clioquinol-related research.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jul","modification":"2024-02-15T05:20:05.454Z","creation":"2020-07-05T07:08:58Z"},"accession":"S-EPMC6571072","cross_references":{"pubmed":["30898518"],"doi":["10.1016/j.pharmthera.2019.03.009"]}}